Residual Disease
Trial of vaccine for triple-negative breast cancer yields ‘encouraging’ results
Nearly 75% of women treated with a novel vaccine designed to prevent triple-negative breast cancer achieved an immune response, according to updated results of a phase 1 trial.
Adjuvant regimen extends survival in early HER2-positive breast cancer
Adjuvant ado-trastuzumab emtansine significantly prolonged survival compared with trastuzumab for certain women with HER2-positive breast cancer, according to long-term results of a randomized phase 3 trial.
VIDEO: SGLT2 inhibition helpful for managing residual cardiometabolic risk
In this Healio | Cardiology Today video exclusive, Chad Morreale, DO, discusses his presentation at the National Lipid Association Scientific Sessions: “Cardiometabolic Disease Patient – How Do I Approach Residual Risk?”
VIDEO: No agreement on using measurable residual disease to guide AML therapy
NEW ORLEANS — In this video perspective, Richard M. Stone, MD, discusses research presented at ASH Annual Meeting and Exhibition looking at the use of measurable residual disease to guide treatment of patients with acute myeloid leukemia.
Residual CVD risk varies; individualized treatments best to combat it
BOSTON — The medical community is better equipped to combat residual CVD risk than previously, but prevention of residual risk should be tailored using a precision medicine approach, a speaker said at the Cardiometabolic Health Congress.